News | News By Subject | News by Disease News By Date | Search News

Leukemia [Acute myelogenous leukemia (AML)] News Articles

Get Our FREE
Industry eNewsletter
email:    
Top Breaking News
4 Fatal Deaths in Seattle Genetics (SGEN)' Early-Stage Trials of AML Drug     12/30/2016
New York’s Cellectis (ALCLS) Looks to 2017 for Clinical Trials of AML Treatment     12/16/2016
FDA Places Clinical Hold on AML Drug Co-Developed by Johnson & Johnson (JNJ) and Genmab A/S (GEN.CO)     9/20/2016
Another Celgene (CELG) Bet Pays Off as Agios (AGIO) Eyes Early Approval of Leukemia Drug     9/8/2016
FDA Berates Celator Pharma (CPXX) for Pushing Unapproved Leukemia Drug to Doctors     9/8/2016
MEI Pharma (MSHL)'s Pracinostat Called a Breakthrough By the FDA     8/1/2016
Ultragenyx (RARE) Rising on Phase III Acute Myeloid Leukemia Data     7/15/2016
Celator Pharma (CPXX) Jumps on Breakthrough Therapy Win for Lead Cancer Drug     5/19/2016
3 Biotechs Getting Another Shot After Failed Trials     4/7/2016
Celator Pharma (CPXX) Stock Jumps 400% Premarket as AML Drug Wows in Phase III Study     3/16/2016
Akinion Halts Further Development of AKN-028 Due to Safety Concerns     3/4/2016
Forty Seven Launches with Half of $75 Million Series A Backed by Google (GOOG) and 100+ Patents     2/26/2016
Novartis AG (NVS)'s Leukemia Drug Gets Breakthrough Designation, Same Week as AstraZeneca PLC (AZN) and Roche (RHHBY) Drugs     2/22/2016
AbbVie (ABBV)'s Venetoclax Wins 3rd Breakthrough Tag from the FDA     1/28/2016
AmerisourceBergen Corporation (ABC) the “Pony to Ride” for Biosimilar Opportunities, Says UBS     3/16/2015

News from Around the Web
Less Is More With Acute Myeloid Leukemia Drug, Erasmus University Medical Center Study     3/17/2011
Mutations in Single Gene Predict Poor Outcomes in Adult Leukemia; Discovery May Guide Treatment for Acute Myeloid Leukemia, Washington University Study     11/11/2010
Protein That Predicts Prognosis Of Leukemia Patients May Also Be A Therapeutic Target, Whitehead Institute and Children's Hospital Boston Reveals     7/12/2010
Umbilical Cord Best Treatment for Childhood Leukaemia     6/8/2007
Leukemia Drug Turns Mini-Molecules Up, Cancer Genes Down     3/1/2007
Researchers Develop New Strategy For The Treatment Of CML     1/18/2007
Role For Proteomics In Identifying Hematologic Malignancies     1/11/2007
Study Identifies Molecular Process Underlying Leukemia     8/22/2006
Cytoplasmic Location Of Shuttling Protein Often Seen With AML     1/20/2005
Perpetual AML Can Arise From Rare Leukemic Stem Cell     6/1/2004
Gene Expression Profiling Yields Prognostic Information For AML Patients     4/14/2004

Press Releases
Novartis AG (NVS) Receives FDA Approval For Rydapt® In Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia (AML) And Three Types Of Systemic Mastocytosis (SM)     4/28/2017
Tolero Pharmaceuticals Presents Preclinical Data On CDK9 Inhibitor Alvocidib And Its Prodrug, TP-1287, At AACR 2017     4/5/2017
Moleculin Biotech (MBRX) Receives Orphan Drug Designation For Annamycin For The Treatment Of Acute Myeloid Leukemia     3/22/2017
Selvita Announces First Patient Dosed In Phase I/II Clinical Trial Of SEL24 In Acute Myeloid Leukemia     3/17/2017
GlycoMimetics, Inc. (GLYC) Completes Enrollment Of Newly Diagnosed AML Patient Cohort In Phase II Clinical Trial Of GMI-1271     3/7/2017
Syros Pharma Reports Discovery Of Novel Genomics Based Approach To Stratifying Patients With Acute Myeloid Leukemia At Cold Spring Harbor Conference     2/27/2017
Cyclacel Pharma (CYCC) Crashes as Leukemia Drug Flunks Key Late-Stage Trial     2/23/2017
Immune Pharma Announces The Launch Of REMAIN, An International Overall Survival Study With Ceplene And Low Dose Proleukin In Remission Maintenance In Acute Myeloid Leukemia     2/17/2017
Another Letdown for Bristol-Myers Squibb (BMY) as Partner Innate Pharma (IPH.PA )'s Leukemia Candidate Flunks Phase II Test     2/6/2017
Regenacy Pharma Release: Pharma's HDAC1,2 Inhibitors Demonstrate Single-Agent And Synergistic Activity With Azacitidine (Vidaza) In Preclinical Models Of Acute Myeloid Leukemia     1/11/2017
MacroGenics (MGNX)’ MGD006 Granted Orphan Drug Status For AML By FDA     1/6/2017
Kura Oncology Receives FDA Clearance To Proceed With Clinical Trial For ERK Inhibitor KO-947 And Nominates KO-539 As Development Candidate For Menin-MLL Inhibitor Program     1/4/2017
Escend Pharma Receives Second Orphan Drug Designation From FDA For ES-3000     12/28/2016
Actinium (ATNM.OB) Announces Submission Of EU Orphan Designation Application For Actimab-A     12/13/2016
Cornerstone Pharmaceuticals, Inc. Presents Phase I Data On CPI-613 In Acute Myeloid Leukemia (AML) And T-Cell Non-Hodgkin's Lymphoma (T-Cell NHL) At American Society of Hematology 2016     12/6/2016

//-->